Gardasil 9

Gardasil 9
Name	Gardasil 9
Tradename	Gardasil 9, Silgard 9
Other names	nine-valent HPV vaccine
Type	Vaccine
Drug class	Viral vaccine
Target	Human papillomavirus

Gardasil 9. It is a nonavalent vaccine designed to protect against infection by several high-risk strains of the human papillomavirus (HPV). Developed by the pharmaceutical company Merck & Co., it is an expanded successor to the original quadrivalent Gardasil vaccine. The vaccine is a critical tool in the prevention of cervical cancer, other anogenital cancers, and genital warts.

Medical uses

Gardasil 9 is indicated for the prevention of diseases caused by nine types of HPV. Its primary medical use is the prevention of precancerous lesions and cancers, including cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, and anal intraepithelial neoplasia. It is also approved for preventing cervical cancer, vulvar cancer, vaginal cancer, anal cancer, and oropharyngeal cancer caused by the covered HPV types. Additionally, it prevents genital warts (condyloma acuminata). The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) recommend routine vaccination for adolescents, typically starting at age 11 or 12, and catch-up vaccination for individuals through age 26. Some national guidelines, such as those from the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), also support its use in certain adults up to age 45 based on shared clinical decision-making.

Composition and mechanism

The vaccine is composed of virus-like particles (VLPs) derived from the major capsid L1 protein of nine HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58. These VLPs are produced via recombinant DNA technology in the yeast Saccharomyces cerevisiae (Baker's yeast). The VLPs are structurally identical to the natural viral capsid but contain no viral genetic material, making them non-infectious. The vaccine also contains an aluminum-based adjuvant, specifically amorphous aluminum hydroxyphosphate sulfate, to enhance the immune response. The mechanism of action involves the induction of a robust humoral immune response, leading to the production of neutralizing antibodies that prevent initial infection by the targeted HPV types at the site of entry, typically the cervix or other mucosal epithelium.

Clinical trials and efficacy

The approval of Gardasil 9 was based on extensive clinical trial data, including a pivotal international study involving over 14,000 women aged 16 to 26. The trial demonstrated nearly 97% efficacy in preventing high-grade cervical, vulvar, and vaginal disease caused by the five additional HPV types (31, 33, 45, 52, 58) not covered by the original Gardasil. Further studies, such as those published in The New England Journal of Medicine, showed sustained efficacy and immunogenicity. Long-term follow-up studies have indicated that protection lasts for at least a decade, with mathematical models from the National Cancer Institute suggesting it may be lifelong. The vaccine has also shown high efficacy in preventing persistent infection and disease in males, as studied in populations including men who have sex with men.

Safety and side effects

The safety profile of Gardasil 9 is well-established through pre-licensure trials and extensive postmarketing surveillance programs like the Vaccine Adverse Event Reporting System (VAERS). The most common side effects are mild and transient, including pain at injection site, erythema, swelling, headache, fever, and nausea. Serious adverse events are rare; syncope (fainting) can occur, so vaccination is typically administered with the recipient seated or lying down. Global monitoring bodies, including the Global Advisory Committee on Vaccine Safety (GACVS) and the Immunization Action Coalition, have consistently reaffirmed its safety, finding no causal link to serious conditions like complex regional pain syndrome or postural orthostatic tachycardia syndrome.

History and development

The development of Gardasil 9 was a direct evolution from the success of the quadrivalent Gardasil, first approved by the FDA in 2006. Researchers at Merck & Co., building on foundational work by scientists like Ian Frazer and Jian Zhou, sought to broaden protection against oncogenic HPV strains. The nine-valent version was designed to cover the seven HPV types responsible for approximately 90% of cervical cancers worldwide. Following successful Phase III clinical trials, Gardasil 9 received FDA approval in December 2014. Subsequent approvals were granted by the European Commission in 2015 and regulatory agencies in numerous countries, including Health Canada and the Therapeutic Goods Administration of Australia.

Society and culture

The introduction and adoption of Gardasil 9 have had significant societal impact, influencing public health policies and cancer prevention strategies globally. Its use is a cornerstone of the WHO's global strategy to eliminate cervical cancer. The vaccine has been the subject of public discourse, sometimes facing vaccine hesitancy fueled by misinformation, which organizations like the American Academy of Pediatrics actively counter. Coverage and access vary widely, with national immunization programs in countries like the United Kingdom, Australia, and Rwanda achieving high uptake, while cost remains a barrier in many low- and middle-income countries. The vaccine's role was highlighted during the COVID-19 pandemic, which caused temporary disruptions to routine vaccination programs worldwide.

Category:Vaccines Category:Merck & Co. brands